Filing Flows › Akebia Therapeutics (AKBA) › Q3 2025
Akebia Therapeutics (AKBA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Akebia Therapeutics (AKBA) reported revenue of $58.8M for the third quarter 2025 (Q3 2025), +57% from a year earlier and -6% from the quarter before. Operating margin was 7.6%, net earnings $540K (0.9% of revenue).
Akebia Therapeutics, Q3 2025: revenue $58.8M (+57% year over year), operating margin 7.6%, net earnings $540K, operating cash flow $28.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $58.8M | -6% | +57% |
| Operating profit | $4.4M | -68% | — |
| Net earnings | $540K | +119% | — |
| Operating cash flow | $28.1M | +26% | — |
| Free cash flow | $28.0M | +26% | — |
What changed
Revenue was $58.8M in Q3 2025, up 57% year over year and down 6% from the previous quarter. Auryxia was the largest line at 72% of revenue. Auryxia added $6.9M year over year (up 19%), 32% of the total change.
Operating profit was $4.4M, a 7.6% margin (up 41.0 points year over year). Total costs grew 9% against revenue growth of 57%. The fastest-growing cost line was Research & development (+76%). Net earnings were $540K. The effective tax rate was 53.2%.
Operating cash flow was $28.1M, 5205% of net earnings. Non-cash charges added back $318K of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $24.0M. Capital expenditures of $77K left free cash flow of $28.0M.
Questions
What was Akebia Therapeutics' revenue in the third quarter 2025?
Akebia Therapeutics (AKBA) reported revenue of $58.8M for the third quarter 2025 (Q3 2025), +57% from a year earlier and -6% from the quarter before.
Was Akebia Therapeutics profitable in the third quarter 2025?
Operating profit was $4.4M (7.6% of revenue) and net earnings $540K.